1. Market Research
  2. > Pharmaceutical Market Trends
  3. > ADC Contract Manufacturing Market (2nd edition), 2015-2025

ADC Contract Manufacturing Market (2nd edition), 2015-2025

  • August 2015
  • -
  • Roots Analysis Private Ltd.
  • -
  • 208 pages

INTRODUCTION
Antibody Drug Conjugates (ADCs) are a new class of therapeutic drugs consisting of a cytotoxic drug linked to a monoclonal antibody. These novel conjugates are believed to be very effective and efficient in treatment of a disease. However, manufacturing such highly potent toxic molecules is accompanied with several known and unknown challenges.

In-house manufacturing of ADCs is rare primarily because of the complex nature of these molecules. Their manufacturing requires both clean room biologic and high containment cytotoxic facilities. This combination is rare and difficult to achieve, requiring significant capital investment.Considering the utilisation rates are likely to be low in the near future, the investment required for setting up such high-containment biologic facilities is a huge financial risk.Even the leading technology providers, including Seattle Genetics and ImmunoGen, are dependent on contract manufacturers to supply the components. Despite the fact that some developers (e.g. Roche) have recently announced their plans to build in-house facilities, the trend of outsourcing is likely to continue for at least the coming decade.

It is worth highlighting there has been a surge in investment activity for facility expansions by a number of CMOs. The concept of one-stop-shop is also gaining traction as CMOs have collaborated with one another in an effort to cater to the increasing demand and to streamline the manufacturing process under one umbrella. Althoughthere are two marketed ADCs till date, a rich and extensive pipeline presents a very big opportunity for the contract manufacturers.

SCOPE OF THE REPORT
The “ADC Contract Manufacturing Market, 2015-2025” report provides an extensive study of the contract manufacturing opportunity for the emerging class of ADCs. The report covers various aspects, such as, identifying CMOs active in this space, their capabilities with respect to ADCs, available capacity (clinical / commercial) for bio-conjugation and geographic location / spread of the facilities.

With several drugs in pipeline, the opportunity for contract manufacturers is likely to increase significantly in the coming years. One of the key objectives of this report is to understand the future potential for CMOs in the ADC market. Amongst other things, the report elaborates on the following key areas:
§ The current state of the market with respect to developmental stage of pipeline products (both clinical / pre-clinical) and indications targeted.
§ Recent partnerships which have taken place over the last five years including product manufacturing agreements, technology collaborations and mergers / acquisitions.
§ CMO investments to develop new / expand existing plants and supporting facilities in order to ensure sufficient production capacity and safe handling of these compounds.
§ Upcoming growth areas and inherent threats to development in the short and long term.
§ Development and sales potential of ADCs in advanced clinical stages; likely outsourcing profile across various steps involved in ADC manufacturing.

The base year for the report is 2015. The report provides short-mid term and long term market forecasts for the period 2015 - 2020 and 2020 - 2025, respectively. We have discussed, in detail, the key drivers behind the growth of the ADC contract manufacturing market. The research, analysis and insights presented in this report are backed by a comprehensive survey on ADC manufacturing capabilities of several CMOs. In addition, we interviewed important stakeholders to solicit their opinions around the future opportunities and challenges which must be considered for a more inclusive growth. Examples of companies we interviewed include Piramal Healthcare, Pierre Fabre, Catalent, Lonza and BSP Pharmaceuticals.

To add robustness to our forecast model, we have provided three market scenarios which vary in terms of the overall ADC commercial sales and the likely cost of manufacturing. The conservative, base and optimistic scenarios represent three different tracks of market evolution.

All actual figures have been sourced and analysed from publicly available information. The figures mentioned in this report are in USD, unless otherwise specified.

RESEARCH METHODOLOGY
Most of the data presented in this report has been gathered by secondary research. As mentioned above, we have also conducted interviews with experts in the area (academia, industry, medical practice and other associations) to solicit their opinions on emerging trends in the market. This is primarily useful for us to draw out our own opinion on how the market will shape up across different regions and drug segments. Where possible, the available data has been checked for accuracy from multiple sources of information.

The secondary sources of information include
§ Annual reports
§ Investor presentations
§ SEC filings
§ Industry databases
§ News releases from company websites
§ Government policy documents
§ Other analysts’ opinion reports

While the focus has been on forecasting the market over the coming ten years, the report also provides our independent view on various technological and non-commercial trends emerging in the industry. This opinion is solely based on our knowledge, research and understanding of the relevant market gathered from various secondary and primary sources of information.

CHAPTER OUTLINES
Chapter 2 provides the executive summary of the insights captured during our research. The summary offers a high level view on the present scenario of ADC contract manufacturing market and where it is headed in the mid-long term.

Chapter 3 provides a general introduction to antibody drug conjugates. We have discussed in detail the components of an ADC. In addition, we have highlighted the advantages of ADC as a therapeutic drug over traditional treatments.

Chapter 4 provides details about the existing ADC therapeutics, both commercial and under clinical/preclinical development. It lists all the companies along with their respective molecules, highlighting their current phase of development and targeted indications. Furthermore, we have analysed the ADC market from the point of view of the commonly used linkers and cytotoxins.

Chapter 5 presents our analysis of the in-house and contract manufacturing of ADCs. There is special focus on CMOs which have capabilities to carry out the different steps in ADC manufacturing. It also includes details about full service providers for ADC manufacturing along with their respective manufacturing sites.
Chapter 6 highlights the regional landscape of CMOs manufacturing different components of ADC, conducting conjugation and / or fill/finish. The analysis has been done for over 40 CMOs by looking at the location of CMOs facilities where these activities are handled.

Chapter 7 includes profiles of 12 leading CMOs in the ADC market. Each company profile includes information such as company overview, financial performance, geographical presence, ADC manufacturing capabilities, ADC manufacturing experience, recent investments for ADC manufacturing and future plans.

Chapter 8 highlights the recent advances in terms of investments made by the CMOs to expand or set up new facilities to support ADC manufacturing. It also provides details about the various partnership models through which the CMOs have collaborated recently. We have analysed the investments to highlight the growing number of investments and the most active players which are leading the capacity expansions.

Chapter 9 presents our detailed analysis of the current and potential future market (in terms of value) for contract manufacturing of ADCs. We have presented the market data for base year 2015 and our forecasts for the period 2015 - 2025. The chapter includes, in detail, our revenue forecast for manufacturing antibody, drug-linker, conjugation, fill/finish and other components involved in ADC production. Due to the uncertain nature of the market, we have presented three different growth tracks outlined as conservative, base and optimistic scenarios.

Chapter 10 provides our analysis of the strengths, weaknesses, opportunities and threats in the ADC contract manufacturing market. This section captures the key elements likely to influence future growth.

Chapter 11 summarises the overall report. In this chapter, we provide a recap of the key takeaways and our independent opinion based on the research and analysis described in previous chapters.

Chapter 12 includes seven interview transcripts based on our discussion with some of the leading CMOs in the ADC manufacturing market. The CMOs interviewed include Piramal Healthcare, Catalent, BSP Pharmaceuticals, Lonza and Pierre Fabre. Two additional CMOs which were interviewed requested the details to be published as anonymous.

Chapters 13 and 14 are appendices and provide the list of companies and tabulated data for all the figures presented in the report.

EXAMPLE HIGHLIGHTS
1. We expect Adcetris and Kadcyla,the two commercially available ADCs,to start generating annual sales of close to USD 1 billion in the near future. In addition to the marketed molecules, there are over 40 candidates in clinical development; of these, 25% are in Phase II & III.
2. Seattle Genetics and Roche, with 7 and 6 molecules in clinical development respectively, currently have the most developed portfolio of ADC molecules.Relatively new entrants include (indicative list, in alphabetical order) AbGenomics, Abzena, Affinicon, Allozyne, Endo Pharmaceuticals, Formation Biologics, Intellect Neurosciences, Kairos Therapeutics, Menarini Biotech, Mersana Therapeutics, Oxford BioTherapeutics, Philochem, Synthon and Zymeworks; emergence of these firms is likely to provide the necessary push, both in terms of technology and innovation.
3. Majority of ADC developers are dependent on contract manufacturers to supply the components.Discussions with senior experts in the industry reveal that around 70% of ADC manufacturing is currently outsourced.
4. In less than two years, there has been a healthy increase in the number of CMOs providing services specific to ADC development; we have identified over 40 such CMOs.There are more than 20 CMOs with capabilities of manufacturing cytotoxics and providing conjugation services. Over 15 CMOs extend their fill/finish capabilities specific to ADC manufacturing.
5. CMOs have been investing heavily to expand their manufacturing capabilities. In the last few years, there have been at least 15 published instances of investments from several CMOs to either expand their respective facilities or acquire new ones. Notably, CARBOGEN AMCIS has been one of the most active players.
6. Collaborations have helped the market reach its current growth trajectory.For example, SAFC and Baxter BioPharma Solutions partnered to manufacture and conduct all the steps of ADC manufacturing to cater to the customer needs. Earlier, Goodwin and Coldstream had collaborated to act as full service providers of ADCs.
7. In the base scenario, we anticipate the overall CMO market for ADC manufacturing to breach the USD 1 billion mark in the coming decade.Infact, there is a strong belief in the market that existing CMO facilities for ADC manufacturing will require expansion to cater to the growing population of pipeline molecules.

Table Of Contents

ADC Contract Manufacturing Market (2nd edition), 2015-2025
1. Preface
1.1. Scope of the Report
1.2. Research Methodology
1.3. Chapter Outlines

2. Executive Summary

3. Introduction
3.1. Chapter Overview
3.2. Parts of an ADC
3.2.1. Antibody
3.2.2. Cytotoxin
3.2.3. Linker: Function and Types
3.3. ADCs: The Revolutionary Technology
3.4. The Traditional Treatments: Naked Antibody and Cytotoxins
3.4.1. Naked Antibodies
3.4.1.1. How Monoclonal Antibody Therapy Works
3.4.2. Naked Cytotoxins
3.5. Conjugated or Armed Antibodies
3.6. Advantages of ADCs over Traditional Therapeutics
3.7. Steps Involved in Manufacturing an ADC

4. ADC Therapeutics: Development Overview
4.1. Chapter Overview
4.2. Three ADCs in the Market
4.3. Analysis of the Development Pipeline
4.3.1. Limited Number of Molecules in Late Stage Development
4.4. Most Commonly Used Cytotoxins in ADC
4.4.1. Cytotoxins Used in ADCs are Highly Potent APIs
4.4.2. Auristatins are the Most Commonly Used Cytotoxins
4.5. Linker: Function and Types
4.5.1. Manufacturing of Linkers
4.5.2. ADC Market by Type of Linker

5. Manufacturing of ADCs: A Market Overview
5.1. Chapter Overview
5.2. Challenges Facing the ADC Manufacturers
5.3. In-House Manufacturing of ADCs
5.4. Majority of ADC Manufacturing is Currently Outsourced
5.5. Presence of Contract Manufacturers
5.5.1. Investment From All Fronts
5.5.2. Start-ups for Contract Manufacturing of ADCs
5.5.3. Contract Manufacturers Collaborating to Provide ADC Capabilities
5.5.4. CMOs Partnering with ADC Technology Providers to Offer Site-Specific Conjugation
5.5.5. CMOs Manufacturing Linkers
5.5.6. CMOs with HPAPI / Cytotoxic Capabilities
5.5.7. Growing Conjugation Capability
5.5.8. Lack of Full Service Providers for ADCs

6. CMOs: Worldwide Landscape
6.1. HPAPI: Unlike APIs, HPAPIs are Mainly Manufactured in Developed Countries
6.2. Conjugation: Lack of CMOs Providing Commercial Conjugation Service in the US
6.3. Fill/Finish: Globally Well Distributed

7. Profiles of Leading Companies
7.1. Chapter Overview
7.2. AbbVie (Abbott Contract Manufacturing)
7.2.1. Company Overview
7.2.2. Financial Performance
7.2.3. ADC Manufacturing Capabilities
7.2.4. ADC Manufacturing Experience
7.2.5. Recent Developments

7.3. Albany Molecular Research (AMRI Global)
7.3.1. Company Overview
7.3.2. Financial Performance
7.3.3. ADC Manufacturing Capabilities
7.3.4. ADC Manufacturing Experience

7.4. BSP Pharmaceuticals
7.4.1. Company Overview
7.4.2. ADC Manufacturing Capabilities
7.4.2.1. ADC Manufacturing Plant
7.4.3. ADC Manufacturing Experience
7.4.4. Recent Developments

7.5. Catalent Pharma Solutions
7.5.1. Company Overview
7.5.2. Financial Performance
7.5.3. Entry in to the ADC Market: Collaboration with Redwood Bioscience
7.5.4. ADC Manufacturing Capabilities
7.5.5. ADC Manufacturing Experience
7.5.6. Recent Developments

7.6. CARBOGEN AMCIS
7.6.1. Company Overview
7.6.2. Financial Performance
7.6.2.1. Dishman Group Business Segments
7.6.3. ADC Manufacturing Capabilities
7.6.4. ADC Manufacturing Experience
7.6.5. Recent Developments

7.7. FUJIFILM Diosynth Biotechnologies
7.7.1. Company Overview
7.7.2. Financial Performance
7.7.3. ADC Manufacturing Capabilities
7.7.4. Recent Developments

7.8. Goodwin Biotechnology
7.8.1. Company Overview
7.8.2. ADC Manufacturing Capabilities
7.8.3. ADC Manufacturing Experience
7.8.4. Recent Developments

7.9. Lonza
7.9.1. Company Overview
7.9.2. Financial Performance
7.9.3. ADC Manufacturing Capabilities
7.9.4. ADC Manufacturing Experience
7.9.5. Recent Developments

7.10. Novasep
7.10.1. Company Overview
7.10.2. Financial Performance
7.10.3. ADC Manufacturing Capabilities
7.10.4. ADC Manufacturing Experience
7.10.5. Recent Developments

7.11. Pierre Fabre Laboratories
7.11.1. Company Overview
7.11.2. Financial Performance
7.11.3. ADC Manufacturing Capabilities
7.11.4. ADC Manufacturing Experience
7.11.5. Recent Developments

7.12. Piramal Healthcare Pharma Solutions
7.12.1. Company Overview
7.12.2. Financial Performance
7.12.3. ADC Manufacturing Capabilities
7.12.4. ADC Manufacturing Experience
7.12.5. Recent Developments

7.13. Sigma-Aldrich Fine Chemicals (SAFC)
7.13.1. Company Overview
7.13.2. Financial Performance
7.13.3. ADC Manufacturing Capabilities
7.13.4. ADC Manufacturing Experience
7.13.5. Recent Developments

8. Recent Developments
8.1. Chapter Overview
8.2. CMOs Investing Heavily in Expanding Capacities
8.2.1. Growing Number of Investments over the years
8.2.2. CARBOGEN AMCIS Leads the Investment Activity
8.3. Deals and Partnerships
8.3.1. Analysis by Type of Partnership

9. Market Size and Forecast
9.1. Chapter Overview
9.2. Forecast Methodology
9.3. ADC Drug Sales Market, 2015 - 2025
9.4. ADC Contract Manufacturing Market, 2015 - 2025
9.4.1. Background
9.4.2. Key Drivers
9.4.3. Overall CMO Market Forecast (Base Scenario), 2015 - 2025
9.4.4. CMO Forecast: Antibody Manufacturing (Base Scenario), 2015- 2025
9.4.5. CMO Forecast: Cytotoxic Drug Manufacturing (Base Scenario), 2015 - 2025
9.4.6. CMO Forecast: Linker Manufacturing (Base Scenario), 2015 - 2025
9.4.7. CMO Forecast: Conjugation (Base Scenario), 2015 - 2025
9.4.8. CMO Forecast: Fill/Finish (Base Scenario), 2015 - 2025
9.4.9. CMO Forecast: Other Activities (Base Scenario), 2015 - 2025

10. SWOT Analysis
10.1. Chapter Overview
10.2. Strengths
10.3. Weaknesses
10.4. Opportunities
10.5. Threats

11. Conclusion
11.1. Outsourcing Trend Likely to Strengthen Further
11.2. ADC Manufacturing: A Need - Gap Analysis
11.3. CMO Market will Evolve as ADCs move from Pipeline to Market
11.4. Rise in Partnerships Will Drive the Growth
11.5. Concluding Remarks

12. Interview Transcripts
12.1. Piramal Healthcare: Dr. Mark Wright, Site Head, Grangemouth
12.2. Pierre Fabre: Christian Bailly, Head of CDMO
12.3. Lonza: Laurent Ducry, ADC RandD
12.4. Catalent Pharma Solutions:Stacy McDonald, Group Product Manager and Jennifer L. Mitcham, Director - Business Development
12.5. BSP Pharmaceuticals: Aldo Braca, CEO
12.6. Leading CMO: Director, Business Development
12.7. Leading CMO: Chief Executive Officer

13. Appendix 1: Tabulated Data

14. Appendix 2: List of Companies and Organisations

List of Figures
Figure 3.1 Parts of Antibody Drug Conjugate
Figure 4.1 ADCs in Clinical Development: Distribution (%) by Phase of Development
Figure 4.2 ADCs in Clinical Development: Distribution (%) by Cytotoxin Used
Figure 5.1 Adcetris: CMO Outsourcing Profile
Figure 5.2 Kadcyla: CMO Outsourcing Profile
Figure 5.3 CDX-011: CMO Outsourcing Profile
Figure 6.1 HPAPI / Cytotoxic Worldwide CMO Facilities
Figure 6.2 HPAPI / Cytotoxic Manufacturing Facilities: Regional Evaluation by Number of Facilities
Figure 6.3 ADC Conjugation: Worldwide CMO Facilities
Figure 6.4 ADC Conjugation Facilities: Regional Evaluation by Number of Facilities
Figure 6.5 ADC Fill / Finish: Worldwide CMO Facilities
Figure 6.6 ADC Fill/Finish Facilities: Regional Evaluation by Number of Facilities
Figure 7.1 AbbVie: Revenues, 2010-2014 (USD Billion)
Figure 7.2 AMRI Global: Revenues, 2010-2014 (USD Million)
Figure 7.3 AMRI Global: Segment Sales, 2014 (USD Million)
Figure 7.4 Catalent: Revenues, 2010-Q3 2015 (USD Million)
Figure 7.5 Catalent: Segment Sales, 2014 (USD Million)
Figure 7.6 Dishman Group: Revenues, 2010-2014 (INR Billion)
Figure 7.7 Dishman: Segment Sales, 2014 (INR Billion)
Figure 7.8 FUJIFILM Diosynth Biotechnologies: Service Portfolio
Figure 7.9 FUJIFILM Group: Revenues, 2010 - 2014 (JPY Billion)
Figure 7.10 FUJIFILM Holdings: Segment Sales, 2014 (JPY Billion)
Figure 7.11 Lonza: Revenues, 2010 - 2014 (CHF Million)
Figure 7.12 Lonza: Segment Sales, 2014 (CHF Million)
Figure 7.13 Novasep: Segment Sales, 2013 (EUR Million)
Figure 7.14 Pierre Fabre Laboratories: Segment Sales, 2014 (EUR Million)
Figure 7.15 Piramal Enterprises: Revenues, 2014 (INR Billion)
Figure 7.16 Piramal Pharmaceutical Business Segment: Revenues, 2014 (INR Billion)
Figure 7.17 SAFC: Revenues, 2010-2014 (USD Million)
Figure 7.18 SAFC: Segment Sales, 2014 (USD Million)
Figure 8.1 CMO Recent ADC Investments: Distribution by Type of Investment
Figure 8.2 ADC CMO: Leading Players by Investments
Figure 8.3 ADC CMO: Distribution by Type of Partnership
Figure 9.1 ADC Sales Forecast, 2015-2025, Base Scenario (USD Million)
Figure 9.2 ADCs: Cost of Manufacturing
Figure 9.3 ADC Contract Manufacturing Market, 2015-2025, Base Scenario (USD Million)
Figure 9.4 ADC Outsourcing: Evolving Landscape
Figure 9.5 CMO Forecast: Antibody Manufacturing, 2015-2025, Base Scenario (USD Million)
Figure 9.6 CMO Forecast: Cytotoxic Drug Manufacturing, 2015-2025, Base Scenario (USD Million)
Figure 9.7 CMO Forecast: Linker Manufacturing, 2015-2025, Base Scenario (USD Million)
Figure 9.8 CMO Forecast: Conjugation, 2015-2025, Base Scenario (USD Million)
Figure 9.9 CMO Forecast: Fill/Finish, 2015-2025, Base Scenario (USD Million)
Figure 9.10 CMO Forecast: Other Activities, 2015-2025, Base Scenario (USD Million)
Figure 11.1 ADC Contract Manufacturing Market, 2015, 2020, 2025 (USD Million)
Figure 11.2 ADC Manufacturing: The Driving Forces


List of Tables
Table 3.1 Cytotoxins for ADC Therapeutics
Table 4.1 ADC Molecules in Clinical Development - Roche / Genentech
Table 4.2 ADC Molecules in Clinical Development - Seattle Genetics
Table 4.3 ADC Molecules in Clinical Development - ImmunoGen
Table 4.4 ADC Molecules in Clinical Development - Immunomedics
Table 4.5 ADC Molecules in Clinical Development - Astellas Pharma / Agensys
Table 4.6 ADC Molecules in Clinical Development - Pfizer / Wyeth
Table 4.7 ADC Molecules in Clinical Development - Sanofi
Table 4.8 ADC Molecules in Clinical Development - Amgen
Table 4.9 ADC Molecules in Clinical Development - AbbVie
Table 4.10 ADC Molecules in Clinical Development - Millennium / Takeda
Table 4.11 ADC Molecules in Clinical Development - Celldex Therapeutics
Table 4.12 ADC Molecules in Clinical Development - Progenics Pharmaceuticals
Table 4.13 ADC Molecules in Clinical Development - Genmab
Table 4.14 ADC Molecules in Clinical Development - ADC Therapeutics
Table 4.15 ADC Molecules in Clinical Development - Bayer Healthcare
Table 4.16 ADC Molecules in Clinical Development - Biotest AG
Table 4.17 ADC Molecules in Clinical Development - Stem CentRx
Table 4.18 ADC Molecules in Clinical Development - Novartis
Table 4.19ADC Molecules in Clinical Development - Synthon
Table 4.20 ADC Molecules in Clinical Development - Menarini Biotech
Table 4.21 ADC Molecules in Clinical Development - Oxford BioTherapeutics
Table 4.22 ADC Molecules in Clinical Development - GSK
Table 4.23 ADC Molecules in Clinical Development - Aspyrian Therapeutics
Table 4.24 ADC Molecules in Preclinical Development - Ambrx
Table 4.25 ADC Molecules in Preclinical Development - Zymeworks
Table 4.26 ADC Molecules in Preclinical Development - Oxford BioTherapeutics
Table 4.27 ADC Molecules in Preclinical Development - Menarini Biotech
Table 4.28 ADC Molecules in Preclinical Development - Novartis
Table 4.29 ADC Molecules in Preclinical Development - Kairos Therapeutics
Table 4.30 ADC Molecules in Preclinical Development - Roche / Genentech
Table 4.31 ADC Molecules in Preclinical Development - Synthon
Table 4.32 ADC Molecules in Preclinical Development - AbbVie
Table 4.33 ADC Molecules in Preclinical Development - AbGenomics
Table 4.34 ADC Molecules in Preclinical Development - ADC Therapeutics
Table 4.35 ADC Molecules in Preclinical Development - Affinicon
Table 4.36 ADC Molecules in Preclinical Development - Allozyne
Table 4.37 ADC Molecules in Preclinical Development - Formation Biologics
Table 4.38 ADC Molecules in Preclinical Development - Astellas
Table 4.39 ADC Molecules in Preclinical Development - Bristol Myers Squibb
Table 4.40 ADC Molecules in Preclinical Development - Celldex Therapeutics
Table 4.41 ADC Molecules in Preclinical Development - Daiichi Sankyo
Table 4.42 ADC Molecules in Preclinical Development - Eli Lilly
Table 4.43 ADC Molecules in Preclinical Development - Endo Pharmaceuticals
Table 4.44 ADC Molecules in Preclinical Development - Mersana Therapeutics
Table 4.45 ADC Molecules in Preclinical Development - Esperance Pharmaceuticals
Table 4.46 ADC Molecules in Preclinical Development - GSK
Table 4.47 ADC Molecules in Preclinical Development - Intellect Neurosciences
Table 4.48 ADC Molecules in Preclinical Development - Merck
Table 4.49 ADC Molecules in Preclinical Development -Heidelberg Pharma
Table 4.50 ADC Molecules in Preclinical Development - National Research Council, Canada
Table 4.51 ADC Molecules in Preclinical Development - Pfizer
Table 4.52 ADC Molecules in Preclinical Development - CytomX Therapeutics
Table 4.53 ADC Molecules in Preclinical Development - Philochem
Table 4.54 ADC Molecules in Preclinical Development - ImmunoGen
Table 4.55 ADC Molecules in Preclinical Development - Genmab
Table 4.56 ADC Molecules in Preclinical Development - Millennium / Takeda
Table 4.57 Most Commonly Used Cytotoxins for ADC Therapeutics
Table 4.58 OEL Bands, Safebridge Consultants
Table 4.59 Pipeline ADCs Using Valine-Citrulline Peptide Linker
Table 4.60 Pipeline ADCs Using Hindered Disulphide Linker
Table 4.61 Pipeline ADCs Using Hydrazone Linker
Table 4.62 Pipeline ADCs Using Maleimidocaproyl Linker
Table 4.63 Pipeline ADCs Using Thioether Linker
Table 4.64 Pipeline ADCs Using Protease Cleavable Peptide Linker
Table 4.65 Pipeline ADCs Using Other Non Cleavable Linker
Table 5.1 ADCs: Matrix View of Outsourced Activities by Molecule
Table 5.2 List of Contract Manufacturers and their Capabilities in ADC Manufacturing
Table 5.3 CMOs Offering ADC Conjugation Services
Table 5.4 Full Service Contract Manufacturers for ADCs
Table 6.1 HPAPI / Cytotoxic: Worldwide ADC CMO Facilities
Table 6.2 Conjugation: Worldwide ADC CMO Facilities
Table 6.3 Fill / Finish: Worldwide ADC CMO Facilities
Table 8.1 ADC CMO Investments
Table 8.2 ADC CMO Deals and Partnerships
Table 9.1 Current Development Phase of ADCs in Clinical Development (Phase II and Higher)
Table 9.2 ADCs: Level of Outsourcing
Table 10.1 SWOT Analysis of ADC Manufacturing Market
Table 10.2 Companies Providing Site-Specific Conjugation Technology
Table 13.1 ADCs in Clinical Development: Distribution (%) by Phase of Development
Table 13.2 ADCs in Clinical Development: Distribution (%) by Cytotoxin Used
Table 13.3 HPAPI / Cytotoxic Manufacturing Facilities: Regional Evaluation by Number of Facilities
Table 13.4 ADC Conjugation Facilities: Regional Evaluation by Number of Facilities
Table 13.5 ADC Fill/Finish Facilities: Regional Evaluation by Number of Facilities
Table 13.6 AbbVie: Revenues, 2010-2014 (USD Billion)
Table 13.7 AMRI Global: Revenues, 2010-2014 (USD Million)
Table 13.8 AMRI Global: Segment Sales, 2014 (USD Million)
Table 13.9 Catalent: Revenues, 2013-Q3 2015 (USD Million)
Table 13.10 Catalent: Segment Sales, 2014 (USD Million)
Table 13.11 Dishman Group: Revenues, 2010-2014 (INR Billion)
Table 13.12 Dishman: Segment Sales, 2014 (INR Billion)
Table 13.13 FUJIFILM Group: Revenues, 2010 - 2014 (JPY Billion)
Table 13.14 FUJIFILM Holdings: Segment Sales, 2014 (JPY Billion)
Table 13.15 Lonza: Revenues, 2010 - 2014 (CHF Million)
Table 13.16 Lonza: Segment Sales, 2014 (CHF Million)
Table 13.17 Novasep: Segment Sales, 2013 (EUR Million)
Table 13.18 Pierre Fabre Laboratories: Segment Sales, 2014 (EUR Million)
Table 13.19 Piramal Enterprises: Revenues, 2014 (INR Billion)
Table 13.20 Piramal Pharmaceutical Business Segment: Revenues, 2014 (INR Billion)
Table 13.21 SAFC: Revenues, 2010-2014 (USD Million)
Table 13.22 SAFC: Segment Sales, 2014 (USD Million)
Table 13.23 CMO Recent ADC Investments: Distribution by Type of Investment
Table 13.24 ADC CMO: Leading Players by Investments
Table 13.25 ADC CMO: Distribution by Type of Partnership
Table 13.26 ADC Sales Forecast, 2015-2025, Base Scenario (USD Million)
Table 13.27 ADC Sales Forecast, 2015 - 2025, Conservative Scenario (USD Million)
Table 13.28 ADC Sales Forecast, 2015 - 2025, Optimistic Scenario (USD Million)
Table 13.29 ADCs: Cost of Manufacturing
Table 13.30 ADC Contract Manufacturing Market, 2015-2025, Base Scenario (USD Million)
Table 13.31 ADC Contract Manufacturing Market, 2015-2025, Conservative Scenario (USD Million)
Table 13.32 ADC Contract Manufacturing Market, 2015-2025, Optimistic Scenario (USD Million)
Table 13.33 CMO Forecast: Antibody Manufacturing, 2015-2025, Base Scenario (USD Million)
Table 13.34 CMO Forecast: Antibody Manufacturing, 2015-2025, Conservative Scenario (USD Million)
Table 13.35 CMO Forecast: Antibody Manufacturing, 2015-2025, Optimistic Scenario (USD Million)
Table 13.36 CMO Forecast: Cytotoxic Drug Manufacturing, 2015-2025, Base Scenario (USD Million)
Table 13.37 CMO Forecast: Cytotoxic Drug Manufacturing, 2015-2025, Conservative Scenario (USD Million)
Table 13.38 CMO Forecast: Cytotoxic Drug Manufacturing, 2015-2025, Optimistic Scenario (USD Million)
Table 13.39 CMO Forecast: Linker Manufacturing, 2015-2025, Base Scenario (USD Million)
Table 13.40 CMO Forecast: Linker Manufacturing, 2015-2025, Conservative Scenario (USD Million)
Table 13.41 CMO Forecast: Linker Manufacturing, 2015-2025, Optimistic Scenario (USD Million)
Table 13.42 CMO Forecast: Conjugation, 2015-2025, Base Scenario (USD Million)
Table 13.43 CMO Forecast: Conjugation, 2015-2025, Conservative Scenario (USD Million)
Table 13.44 CMO Forecast: Conjugation, 2015-2025, Optimistic Scenario (USD Million)
Table 13.45 CMO Forecast: Fill/Finish, 2015-2025, Base Scenario (USD Million)
Table 13.46 CMO Forecast: Fill/Finish, 2015-2025, Conservative Scenario (USD Million)
Table 13.47 CMO Forecast: Fill/Finish, 2015-2025, Optimistic Scenario (USD Million)
Table 13.48 CMO Forecast: Other Activities, 2015-2025, Base Scenario (USD Million)
Table 13.49 CMO Forecast: Other Activities, 2015-2025, Conservative Scenario (USD Million)
Table 13.50 CMO Forecast: Other Activities, 2015-2025, Optimistic Scenario (USD Million)
Table 13.51 CMOs with HPAPI and Cytotoxics Production Facilities

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
2016 Immunodiagnostic Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales Segment Forecasts for 100 Special Chemistry, Drug of Abuse, Endocrine Function, Immunoprotein, Therapeutic Drug Monitoring, and Tumor Marker Tests,  Opport

2016 Immunodiagnostic Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales Segment Forecasts for 100 Special Chemistry, Drug of Abuse, Endocrine Function, Immunoprotein, Therapeutic Drug Monitoring, and Tumor Marker Tests, Opport

  • $ 47500
  • Industry report
  • October 2016
  • by Venture Planning Group

This new 33-company survey from VPGMarketResearch.com contains 1,650 pages and 890 tables. The report provides a granular strategic analysis of over 100 clinical chemistry, TDM, endocrine, cancer, immunoprotein ...

2016 Tumor Markers in 32 Countries: Supplier Shares and Strategies, Sales Segment Forecasts by Test--Oncogenes, Biochemical Markers, Lymphokines, GFs, CSFs, Hormones, Immunohistochemical Stains--Emerging Technologies, Opportunities for Suppliers

2016 Tumor Markers in 32 Countries: Supplier Shares and Strategies, Sales Segment Forecasts by Test--Oncogenes, Biochemical Markers, Lymphokines, GFs, CSFs, Hormones, Immunohistochemical Stains--Emerging Technologies, Opportunities for Suppliers

  • $ 47400
  • Industry report
  • October 2016
  • by Venture Planning Group

This new 33-country survey from VPGMarketResearch.com contains over 1,300 pages and 500 tables. The survey is designed to assist diagnostics industry executives, as well as companies planning to diversify ...

2016 Cancer Diagnostic Testing Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales Segment Forecasts by Tumor Marker--Oncogenes, Biochemical Markers, Lymphokines, GFs, CSFs, Hormones, Immunohistochemical Stains--Technology Trends

2016 Cancer Diagnostic Testing Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales Segment Forecasts by Tumor Marker--Oncogenes, Biochemical Markers, Lymphokines, GFs, CSFs, Hormones, Immunohistochemical Stains--Technology Trends

  • $ 47400
  • Industry report
  • October 2016
  • by Venture Planning Group

This new 33-country survey from VPGMarketResearch.com contains over 1,300 pages and 500 tables. The survey is designed to assist diagnostics industry executives, as well as companies planning to diversify ...


ref:plp2015

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.